Sign in
SuspendedPhase 2/3

CBD Oil for Reducing Emotional Impact of COVID-19

Key facts

Who runs it
University of Texas at Austin
Where
Austin, United StatesSee the site
Trial code
Status
Suspended
Phase
Phase 2/3
People taking part
200 people, planned
Started
4 Dec 2020
Ended
31 Dec 2023
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • CBD Isolate
  • Full Spectrum CBD Oil
  • Broad-Spectrum CBD Oil
  • Placebo Oil
Record updated
22 November 2023
Why it stopped
Suspended (The UT IRB determined that CBD oil is being used as a drug as defined by the FDA. Therefore, an IND must be obtained for the use of CBD oil in this research study in accordance with FDA regulations, 21 CFR 312.)

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Displays elevated symptom scores on one or more of the following established assessment instruments for depression (PROMIS-Depression), anxiety (PROMIS-Anxiety), Anger (PROMIS-Anger), sleep disturbance (PROMIS-Sleep); or Alcohol/Substance (PROMIS-Alcohol; PROMIS- Substance Use)
  • Age between 18 to 70
  • Fluent in English
  • Has home access to the Internet
  • Willingness to provide signed informed consent
  • Willingness to refrain from all non-study CBD products during the 6-week study period
  • Willing to complete a brief pre-study 7-day online symptom monitoring log
  • Currently residing in the United States

Who cannot take part

  • Currently taking seizure medications such as valproate, lamotrigine, or clobazam
  • Currently taking thyroid medications such as levothyroxine
  • Currently taking heart rhythm medications such as amiodarone
  • Currently taking anti-hypertension medications
  • History of a suicide attempt within the past 6 months
  • Any medical problem that would preclude participating in the study including liver disease
  • History of adverse reaction to CBD oil or other CBD products
  • Allergic to coconut oil
  • Current use of warfarin or other prescribed blood thinners,
  • Pregnant or planning to become pregnant within the next 6 weeks

Where in United States

  • University of Texas at Austin, Laboratory for the Study of Anxiety DisordersAustin, United States

About the trial

What the trial wants to find out

Our purpose is to conduct a 4-arm placebo-controlled clinical trial to investigate the relative clinical efficacy of 300 mg. of pure hemp-derived CBD isolate, 300 mg. of full spectrum CBD oil, 300 mg. of broad- spectrum CBD Oil, or Placebo oil among adults presenting with COVID-19 -induced stress reactions including one or more of the following: anxiety, depression, anger, substance use, or sleep disturbance.

The 4 groups in the trial

  • CBD-Isolate 300 mg.Existing treatment, for comparison

    Nightly oral administration of 300 mg. of CBD-Isolate for 28 consecutive days

    Treatment: CBD Isolate

  • Full-Spectrum CBD Oil 300 mg.Existing treatment, for comparison

    Nightly oral administration of 300 mg. of Full Spectrum CBD Oil for 28 consecutive days

    Treatment: Full Spectrum CBD Oil

  • Broad-Spectrum CBD oil 300 mg.Existing treatment, for comparison

    Nightly oral administration of 300 mg. of Broad-Spectrum CBD Oil for 28 consecutive days

    Treatment: Broad-Spectrum CBD Oil

  • Placebo OilPlacebo, for comparison

    Nightly oral administration of 300 mg. of Placebo Oil for 28 consecutive days

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Use of CBD Oil for Reducing the Negative Emotional Impact of COVID-19: A Randomized Placebo-Controlled Clinical Trial
Record updated
22 November 2023